The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Vedanta Biosciences Completes $68 Million Series D Financing
Finance

Vedanta Biosciences Completes $68 Million Series D Financing

JUL 21, 2021
DNA Genotek & Diversigen announce two $50K grants for multi-omics research
Finance

DNA Genotek & Diversigen announce two $50K grants for multi-omics research

JUL 8, 2021
Engineered yeast probiotic developed to treat inflammatory bowel disease
Biotics and Supplements

Engineered yeast probiotic developed to treat inflammatory bowel disease

JUL 7, 2021
Fecal transplant plus fibre improves insulin sensitivity in severely obese
Biotics and Supplements

Fecal transplant plus fibre improves insulin sensitivity in severely obese

JUL 6, 2021
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Editor's Choice

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

JUL 2, 2021
CN Bio’s PhysioMimix™ Adopted by King’s College London to Investigate Chronic Liver Disease
Pharma & Human Health

CN Bio’s PhysioMimix™ Adopted by King’s College London to Investigate Chronic Liver Disease

JUL 1, 2021
BiomeBank submits for market authorisation of microbial therapy
Pharma & Human Health

BiomeBank submits for market authorisation of microbial therapy

JUL 1, 2021
MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy
Oncology

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy

JUN 28, 2021
Dieting and its effect on the gut microbiome
Pharma & Human Health

Dieting and its effect on the gut microbiome

JUN 23, 2021
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
Clinical & Manufacturing

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

JUN 23, 2021
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
Finance

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

JUN 22, 2021